The European Medicines Agency (EMA) approved nemolizumab for prurigo nodularis in adults and atopic dermatitis in individuals 12 and older. This is a significant advancement as it's the first monoclonal antibody to specifically target and block interleukin (IL)-31, a key player in itch and inflammation. Furthermore, case studies are highlighting its effectiveness in relieving itch across various other conditions.
